Petros Grivas, ESMO 2019 – Advances in metastatic urothelial cancer
We joined Petros Grivas (University of Washington School of Medicine) at ESMO 2019 to discuss immune checkpoint inhibitors and novel agents in the treatment of metastatic urothelial cancer.
1. How have immune checkpoint inhibitors changed the treatment landscape for metastatic urothelial cancer? (0:04)
2. What progress has been made in identifying biomarkers of response to immune checkpoint inhibitors in urothelial cancer? (1:35)
3. What is the potential for combined treatment approaches using programmed cell death 1 (PD-1) and CTLA-4 inhibitors in urothelial cancer? (2:48)
4. How can we best manage toxicity from immune checkpoint inhibitors? (4:32)
5. Which novel agents are in clinical development for metastatic urothelial cancer? (6:37)
Filmed at the European Society for Medical Oncology (ESMO) Congress 2019, Barcelona, Spain.
Speaker disclosure: Petros Grivas has acted as a consultant for AstraZeneca, Bayer, Biocept, Bristol-Myers Squibb, Clovis Oncology, Dendreon, Driver, EMD Serono, Exelixis, Foundation Medicine, Genentech, Genzyme, Heron Therapeutics, Janssen, Merck & Co., Mirati Therapeutics, Pfizer, Seattle Genetics and QED Therapeutics. He has been involved in educational programs with Bristol-Myers Squibb, Genentech Research Funding to Institution, AstraZeneca, Bayer, Genentech/Roche, Merck & Co., Mirati Therapeutics, Oncogenex, Pfizer, Clovis Oncology, Bavarian Nordic, Immunomedics, Debiopharm and Bristol-Myers Squibb.
touchONCOLOGY.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via free-to-access content in multimedia formats.
Share this Video
Related Videos In Bladder Cancer
Sebastian Schmid, ESMO 2022: RACE-IT – RAdiation therapy before radical CystEctomy combined with ImmunoTherapy in advanced bladder cancer
Patients with locally advanced bladder cancer have a poor prognosis despite surgical therapy. Prof. Sebastian Schmid (Technical University of Munich, Munich, Germany) joins touchONCOLOGY to discuss the unmet needs in the treatment of locally advanced bladder cancer, and also discusses the feasibility, safety and efficacy of neoadjuvant radio-immunotherapy following radical cystectomy in patients with locally […]
Robert Jones, ASCO 2022: Maintenance cabozantinib following chemotherapy for metastatic urothelial carcinoma – Phase 2 ATLANTIS trial
Cabozantinib is a targeted therapy used to treat many forms of cancers. Prof. Robert Jones (University of Glasgow, Scotland, United Kingdom) discusses the rationale, design, and findings of the randomised phase 2 ATLANTIS trial, of maintenance cabozantinib following chemotherapy for metastatic urothelial carcinoma. Questions: What is the rationale for the use of cabozantinib in the […]
Neal Shore, AACR 2022: KEYNOTE-992 a Phase 3 Study of Pembrolizumab in Muscle-invasive Bladder Cancer
touchONCOLOGY were delighted to talk with Dr. Neal Shore (GenesisCare; Carolina Urologic Research Center, Myrtle Beach, SC, USA) to discuss the phase 3 study of pembrolizumab plus chemoradiotherapy in the treatment of muscle-invasive bladder cancer. The abstract ‘KEYNOTE-992: A randomized phase 3 trial of pembrolizumab versus placebo in patients with muscle-invasive bladder cancer receiving concurrent […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!